Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Next Previous
Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary) ; Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRISMA-3_OLE
  • Sponsors Rovi

Most Recent Events

  • 18 Oct 2022 Results (of open label extension (OLE) phase of the PRISMA-3 study) assessing extrapyramidal symptoms of Risperidone ISM in patients with schizophrenia presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
  • 18 Oct 2022 Results from NCT03160521 and NCT03870880, evaluating the cardiovascular safety of Risperidone, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
  • 04 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top